LIVInG With chrONic Cancer TrEatments (LONGEVITI) Study

NCT05645510 | Recruiting

• 1 other identifier: HREBA.CC-22-0196
• Study Type: observational
• Target: 75
• Locations: 1 country
• Sites: 1

Brief Summary

People with advanced chronic cancers are now living for many years as a result of new targeted anti-cancer treatments. Many of these treatments are quite new and people may take them for months, even years, as long as the treatments are helping. The purpose of this study is to help understand how to best support people receiving these treatments.

Conditions

Cancer; Tyrosine Kinase Mutation; Breast Cancer; Melanoma; Multiple Myeloma; Chronic Leukemia; Prostate Cancer; Ovarian Cancer; Colorectal Cancer; Lung Cancer

Outcome Measures

Primary Outcomes (1)

• Interview

  Interview to learn the experiences of people living with incurable cancers

  3 months

Eligibility Criteria

• Age: 18 Years - 90 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

people with cancer taking oral anti-cancer agents over the long term

Sponsors & Collaborators

• University of Alberta: lead
• Social Sciences and Humanities Research Council of Canada: collaborator

Study Sites (1)

Edith Pituskin

Edmonton, Alberta, T6G 1C9, Canada

RECRUITING

MeSH Terms

Conditions

Neoplasms; Breast Neoplasms; Melanoma; Multiple Myeloma; Prostatic Neoplasms; Ovarian Neoplasms; Colorectal Neoplasms; Lung Neoplasms

Condition Hierarchy (Ancestors)

Neoplasms by Site; Breast Diseases; Skin Diseases; Skin and Connective Tissue Diseases; Neuroendocrine Tumors; Neuroectodermal Tumors; Neoplasms, Germ Cell and Embryonal; Neoplasms by Histologic Type; Neoplasms, Nerve Tissue; Nevi and Melanomas; Skin Neoplasms; Neoplasms, Plasma Cell; Hemostatic Disorders; Vascular Diseases; Cardiovascular Diseases; Paraproteinemias; Blood Protein Disorders; Hematologic Diseases; Hemic and Lymphatic Diseases; Hemorrhagic Disorders; Lymphoproliferative Disorders; Immunoproliferative Disorders; Immune System Diseases; Genital Neoplasms, Male; Urogenital Neoplasms; Genital Diseases, Male; Genital Diseases; Urogenital Diseases; Prostatic Diseases; Male Urogenital Diseases; Endocrine Gland Neoplasms; Ovarian Diseases; Adnexal Diseases; Genital Diseases, Female; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Genital Neoplasms, Female; Endocrine System Diseases; Gonadal Disorders; Intestinal Neoplasms; Gastrointestinal Neoplasms; Digestive System Neoplasms; Digestive System Diseases; Gastrointestinal Diseases; Colonic Diseases; Intestinal Diseases; Rectal Diseases; Respiratory Tract Neoplasms; Thoracic Neoplasms; Lung Diseases; Respiratory Tract Diseases

Central Study Contacts

Edith Pituskin, PhD

CONTACT

7804328221; pituskin@ualberta.ca

Meredith Porter Hogg, MN

CONTACT

lngeviti@ualberta.ca

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: November 30, 2022
• First Posted: December 9, 2022
• Study Start: November 24, 2022
• Primary Completion: November 30, 2025
• Study Completion (Estimated): May 30, 2026
• Last Updated: April 15, 2025

Record last verified: 2025-04

Locations

CA (1)